Menu Search
Equities

Cochlear Ltd

OC5:BRN

Cochlear Ltd

Actions
  • Price (CHF)96.71
  • Today's Change0.00 / 0.00%
  • Shares traded440.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 20 2017.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Company’s products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.

  • Revenue in AUD (TTM)2.24bn
  • Net income in AUD356.80m
  • Incorporated1983
  • Employees5.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		COH:ASX since
announced		Transaction
value
Neurelec SAAnnounced25 Jun 202425 Jun 2024Announced-7.89%--
Data delayed at least 20 minutes, as of Nov 22 2024 03:23 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.